The six-month randomized controlled trial (RCT) enrolled 437 participants at 36 sites across the US The study demonstrated no statistically significant difference between treatment arms in any ...
UPPSALA, Sweden, Feb. 10, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces the company will collaborate with ApexB.io and Magellan Rx Management to further research on ...
Study evaluating efficacy of MODIA®, a digital therapeutic, in addition to clinician supervised medication-assisted treatment programs for individuals with opioid use disorder (OUD) The study enrolled ...
Orexo will start a new study of its modia app – used to treat people with opioid use disorder – to test how it performs in real-world settings. The Swedish drugmaker has teamed up with consultancy ...
UPPSALA, Sweden, Oct. 18, 2021 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announced the publication of a manuscript, "A Personalized ...
UPPSALA, Sweden, Oct. 11, 2023 /PRNewswire/ -- Orexo AB (publ.),, today reports top line results after having completed a study evaluating the efficacy of MODIA in combination with sublingual ...
- The Covid-19 pandemic has highlighted the urgent need for additional resources to prevent overdose deaths, which have reached an all-time high with an increase of 21 percent 1 - The ...
The Covid-19 pandemic has highlighted the urgent need for additional resources to prevent overdose deaths, which have reached an all-time high with an increase of 21 percent[1] The medication-assisted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results